COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING

NOTE: This meeting will be held virtually via Zoom webinar.

Thursday, September 17, 2020
1:00 P.M. to 4:00 P.M. (Eastern)

Access Information

<table>
<thead>
<tr>
<th>Smartphone/Web</th>
<th>Dial-In</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://magellanhealth.zoom.us/s/93047561955">https://magellanhealth.zoom.us/s/93047561955</a></td>
<td>+1 312 626 6799 (US Toll) OR +1 646 558 8656 (US Toll)</td>
</tr>
<tr>
<td>Webinar ID: 930 4756 1955</td>
<td>Webinar ID: 930 4756 1955</td>
</tr>
<tr>
<td>Password: AUXNP0</td>
<td>Password: 465480</td>
</tr>
</tbody>
</table>

AGENDA

I. Call to Order and Welcome

II. Executive Session (upon request)

III. Old Business
   a. Approval of Meeting Minutes

IV. New Business
   a. New Products to Market to be reviewed as single products:
      i. Xepi™ (Antibiotics, Topical)
      ii. Zeposia® (Multiple Sclerosis Agents)
   b. New Products to Market to be reviewed along with their respective classes:
      i. Xcopri™ (Anticonvulsants)
      ii. Kynmobi™ (Antiparkinson’s Agents)
      iii. Caplyta™ (Antipsychotics)
      iv. Nexletol™ and Nexlizet™ (Lipotropics, Other)
      v. Dayvigo™ (Sedative Hypnotics)

V. Therapeutic Classes with Recommended Changes
   a. Alzheimer’s Agents
   b. Anticonvulsants
      i. Anticonvulsants: First Generation
      ii. Anticonvulsants: Second Generation (includes new agent Xcopri™)
      iii. Anticonvulsants: Carbamazepine Derivatives
   c. Antimigraine Agents, Other (Anti-Migraine: CGRP Inhibitors)
   d. Antiparkinson’s Agents (includes new agent Kynmobi™)
   e. Antipsychotics
      i. First-Generation Antipsychotics
      ii. Second-Generation Antipsychotics (includes new agent Caplyta™)
      iii. Antipsychotics: Injectable
   f. Lipotropics, Other (includes new agents Nexletol™ and Nexlizet™)
      i. Familial Hypercholesterolemia Agents
      ii. Lipotropics: Bile Acid Sequestrants
iii. Lipotropics: Cholesterol Absorption Inhibitor
iv. Lipotropics: Fibric Acid Derivatives
v. Lipotropics: Niacin Derivatives
vi. Lipotropics: Omega-3 Fatty Acids
vii. Lipotropics: PCSK9s
g. Neuropathic Pain
h. PAH Agents, Oral and Inhaled
i. Sedative Hypnotics (includes new agent Dayvigo™)
j. Stimulants and Related Agents
   i. Narcolepsy Agents
   ii. Stimulants and Related Agents

VI. Consent Agenda
   a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

<table>
<thead>
<tr>
<th>Therapeutic Class</th>
<th>Medication Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angiotensin Modulator Combinations</td>
<td>Beta-Blockers</td>
</tr>
<tr>
<td>Angiotensin Modulators</td>
<td>Bladder Relaxant Preparations</td>
</tr>
<tr>
<td>Antianginal &amp; Anti-ischemic</td>
<td>BPH Treatments</td>
</tr>
<tr>
<td>Antiarrhythmics, Oral</td>
<td>Calcium Channel Blockers</td>
</tr>
<tr>
<td>Anticoagulants</td>
<td>Lipotropics, Statins</td>
</tr>
<tr>
<td>Antidepressants, Other</td>
<td>Movement Disorders</td>
</tr>
<tr>
<td>Antidepressants, SSRIs</td>
<td>Platelet Aggregation Inhibitors</td>
</tr>
<tr>
<td>Antidepressants, Tricyclic</td>
<td>Skeletal Muscle Relaxants</td>
</tr>
<tr>
<td>Antimigraine Agents, Triptans</td>
<td>Smoking Cessation</td>
</tr>
<tr>
<td>Axiolytics</td>
<td></td>
</tr>
</tbody>
</table>

VII. Adjournment
   a. Schedule of Upcoming Meetings
      i. November 19, 2020
   b. Collection of Travel Vouchers

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at: https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml.